Regulatory T cells (Treg) can improve disease outcomes for Alzheimer's disease. However, prior use of polyclonal Tregs have reduced potency. To resolve this we will confer amyloid beta specificity through the transgenic T-cell receptor or chimeric antigen receptor to target diseased brain tissues.